Cargando…
Exploring potential biomarkers for lung adenocarcinoma using LC-MS/MS metabolomics
BACKGROUND: The average 5-year survival rate of lung adenocarcinoma patients is only 15% to 17%, which is primarily due to late-stage diagnosis and a lack of specific prognostic evaluations that can recommend effective therapies. Additionally, there is no clinically recognized biomarker that is effe...
Autores principales: | Mo, Liang, Wei, Bing, Liang, Renji, Yang, Zhi, Xie, Shouzhi, Wu, Shengrong, You, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177994/ https://www.ncbi.nlm.nih.gov/pubmed/32316791 http://dx.doi.org/10.1177/0300060519897215 |
Ejemplares similares
-
Integrated LC-MS/MS system for plant metabolomics
por: Sawada, Yuji, et al.
Publicado: (2013) -
LC-MS/MS based metabolomics and proteomics reveal candidate biomarkers and molecular mechanism of early IgA nephropathy
por: Zhang, Di, et al.
Publicado: (2022) -
Establishment of Protocols for Global Metabolomics by LC-MS for Biomarker Discovery
por: Saigusa, Daisuke, et al.
Publicado: (2016) -
Study on plasma metabolomics for HIV/AIDS patients treated by HAART based on LC/MS-MS
por: Lao, Donghui, et al.
Publicado: (2022) -
Organization of GC/MS and LC/MS metabolomics data into chemical libraries
por: DeHaven, Corey D, et al.
Publicado: (2010)